Broad sector stumbles; BioCryst soars on drug study

BOSTON - Drug stocks were mired in red Friday afternoon, but shares of BioCryst Pharmaceuticals soared on positive results from a study for the company's new lymphoma treatment.

The Amex Pharmaceutical Index ($DRG) slipped 1.5% to 248.21 and the Amex Biotechnology Index ($BTK) slid 1.7% to 611.94.

The Dow Jones Industrial Average (XX:DJII) declined almost 90 points to 8,244.

Most of Big Pharma was trading lower. Bristol-Myers Squibb (BMY), Eli Lilly & Co., (LLY) and Pfizer Inc. (PFE) were the lead decliners on the U.S. side, with shares down at least 2%.

Danish group H. Lundbeck A/S (HLUKY) was the mover of note among the large foreign drug makers, with shares falling about 3% to $22.90 after seeing two straight days of significant gains.

No comments:

Post a Comment

Superhit News

News Archive